Why have it done in China specifically?

China offers this therapy at a significantly lower cost—approximately $3,500 per year—compared to $30,000–$50,000 annually in the United States or Western Europe, making it accessible for long-term maintenance. Chinese pulmonologists are experienced in managing antifibrotic therapy, with high patient volumes in specialized interstitial lung disease centers. Hospitals in major cities (e.g., Beijing, Shanghai, Guangzhou) use the same internationally approved pirfenidone formulations and follow global monitoring guidelines. Combined with affordable quarterly LFT and PFT testing, China provides a cost-effective option without compromising standard-of-care quality.